Profiles

Keywords
Last Name
Institution

Nancy Reau

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Digestive Diseases and Nutrition
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 15756529900.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119. PMID: 28350558.
      View in: PubMed
    2. Tran TT, Ahn J, Reau NS. Corrigendum: ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Nov; 111(11):1668. PMID: 27808138.
      View in: PubMed
    3. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 Dec; 64(6):2210-2218. PMID: 27506929.
      View in: PubMed
    4. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 Nov; 151(5):893-901.e1. PMID: 27486034.
      View in: PubMed
    5. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 Oct 15; 63(8):1042-1048. PMID: 27444413.
      View in: PubMed
    6. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 Jul; 36(7):925-8. PMID: 27306302.
      View in: PubMed
    7. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Vila RP, Liu L, Pedrosa M, Moller J, Reau N. Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 Jul; 111(7):1077. PMID: 27356843.
      View in: PubMed
    8. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30. PMID: 26642977.
      View in: PubMed
    9. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, Reau N. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 Jun; 111(6):845-51. PMID: 27045929; PMCID: PMC4897007.
    10. Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9. PMID: 26782133.
      View in: PubMed
    11. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196. PMID: 26832651.
      View in: PubMed
    12. Reau N, Fried MW, Nelson DR, Brown RS, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502. PMID: 26509462.
      View in: PubMed
    13. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17. PMID: 26575258.
      View in: PubMed
    14. Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v. PMID: 26466649.
      View in: PubMed
    15. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44. PMID: 25942724.
      View in: PubMed
    16. Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med. 2015; 7:11-20. PMID: 25926761; PMCID: PMC4403691.
    17. Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5. PMID: 25742912.
      View in: PubMed
    18. Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau N, Meltzer DO, Jensen D. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6. PMID: 24100752.
      View in: PubMed
    19. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91. PMID: 24806752.
      View in: PubMed
    20. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9. PMID: 24493069.
      View in: PubMed
    21. Reau N. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6. PMID: 23962550.
      View in: PubMed
    22. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305. PMID: 23269576.
      View in: PubMed
    23. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat. 2012; 2012:138302. PMID: 23094146; PMCID: PMC3472509.
    24. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, Satoskar R, Devoss A, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. Therap Adv Gastroenterol. 2012 Sep; 5(5):275-83. PMID: 22973414; PMCID: PMC3437533.
    25. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32. PMID: 22554357.
      View in: PubMed
    26. Mufti AR, Reau N. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69. PMID: 22541697.
      View in: PubMed
    27. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82. PMID: 22314423.
      View in: PubMed
    28. Desai AP, Reau N. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95. PMID: 21867932.
      View in: PubMed
    29. Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102. PMID: 22239499; PMCID: PMC3489051.
    30. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8. PMID: 21063395.
      View in: PubMed
    31. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71. PMID: 19448563.
      View in: PubMed
    32. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8. PMID: 18796095; PMCID: PMC2752675.
    33. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008 Aug; 62(2):224-8. PMID: 18480168.
      View in: PubMed
    34. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x. PMID: 18242505.
      View in: PubMed
    35. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y). 2006 Jul; 2(7):504-508. PMID: 28289353.
      View in: PubMed
    Reau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description